

- COPENHAGEN
- HEIDELBERG
- MILAN

CHIBA
YOKOHAMA

SEATTLE

Modalities at this site:

Mammalian

Cell Therapy

mRNA



YOKOHAMA FACILITY

New State-of-the-Art Facility in Japan


AGC Biologics is constructing a new site in Yokohama, Japan with plans to be GMP-ready in 2027. This site will expand our network capabilities in Japan, to meet growing global demand for biopharmaceutical CDMO services by offering cell therapy, mammalian, and mRNA-LNP services.

The new four-story facility will encompass 16,764m² of floor space and will include earthquake and tsunami protection. Solar panels will help with private power generation. The facility will feature **dedicated spaces for process development (PD), quality control**

(QC), and manufacturing, including an automated warehouse, to ensure efficient workflows.

Located adjacent to the AGC Yokohama Technical Center, which employs over 1,000 scientists working on new technology innovations and provides cell therapy process development services while the new site comes online. This site will leverage the processes and expertise of our other facilities across the globe, which have over 30 years of experience providing end-to-end services.





Cell Therapy Services

- AGC Bio's expertise with internalizing autologous and allogeneic processes from the Center of Excellence in Milan
- Process transfer, development, cell manipulation, and engineering
- 2 x 25 L wave reactors
- 2 x CliniMACS Prodigy® platforms
- Capabilities for gene modification of cells by LVV/ RVV
- 6 x Grade B clean rooms
- Expertise in commonly used cell therapy types
 - T-cells
 - HSC / CD34
 - NK cells
 - MSC
 - Immune cells

Mammalian Services

- Process development services available at nearby Chiba site to begin projects
- Recombinant protein and monoclonal antibodies
- 4 x 2,000 L SUB
- 2 x 5,000 L SUB
- 2 x purification lines (1 of 2 lines to be implemented in the future)
- Titters up to 8 g/l for a single batch
- Offering one of the largest single-use bioreactors for a CDMO in Japan

mRNA Services

- In-network pDNA supply
- mRNA process development and commercial production
- Production scales 1 - 50 g (single-use bag)
- 2 x IVT lines (0.5 - 25 L wave)
- 2 x purification lines - ÄKTA ready
- 2 x LNP lines - Nano Assemblr (1 of 2 lines to be implemented in the future)

Globally Aligned Quality System

- Documentation, policies, procedures
- Part of a global network of sites sharing best practices to meet clinical and commercial needs

